Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib for immuno-metabolic depression
2021-003850-21Phase 3Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Celecoxib + treatment as usual with Placebo + treatment as usual (2 arms). Started Jun 2022; status: active.
02
Drugs
celecoxib
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2021-003850-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003850-21.